Individuals with disabilities may require specific medications in pregnancy. The prevalence and patterns of medication use, overall and for medications with known teratogenic risks, are largely unknown.
Methods:
This population-based cohort study in Ontario, Canada, 2004–2021, comprised all recognized pregnancies among individuals eligible for public drug plan coverage. Included were those with a physical (n = 44,136), sensory (n = 13,633), intellectual or developmental (n = 2,446) disability, or multiple disabilities (n = 5,064), compared with those without a disability (n = 299,944). Prescription medication use in pregnancy, overall and by type, was described. Modified Poisson regression generated relative risks (aRR) for the use of medications with known teratogenic risks and use of ≥2 and ≥5 medications concurrently in pregnancy, comparing those with versus without a disability, adjusting for sociodemographic and clinical factors.
Results:
Medication use in pregnancy was more common in people with intellectual or developmental (82.1%), multiple (80.4%), physical (73.9%), and sensory (71.9%) disabilities, than in those with no known disability (67.4%). Compared with those without a disability (5.7%), teratogenic medication use in pregnancy was especially higher in people with multiple disabilities (14.2%; aRR 2.03, 95% confidence interval [CI]: 1.88–2.20). Furthermore, compared with people without a disability (3.2%), the use of ≥5 medications concurrently was more common in those with multiple disabilities (13.4%; aRR 2.21, 95% CI: 2.02–2.41) and an intellectual or developmental disability (9.3%; aRR 2.13, 95% CI: 1.86–2.45).
Interpretation:
Among people with disabilities, medication use in pregnancy is prevalent, especially for potentially teratogenic medications and polypharmacy, highlighting the need for preconception counseling/monitoring to reduce medication-related harm in pregnancy.
Get full access to this article
View all access options for this article.
References
1.
DawJR, MintzesB, LawMR, et al.Prescription drug use in pregnancy: A retrospective, population-based study in British Columbia, Canada (2001–2006). Clin Ther, 2012; 34(1):239–249.e2; doi: 10.1016/j.clinthera.2011.11.025
2.
LeongC, ChateauD, DahlM, et al.Prescription medication use during pregnancies that resulted in births and abortions (2001–2013): A retrospective population-based study in a Canadian population. PLoS One, 2019; 14(3):e0211319; doi: 10.1371/journal.pone.0211319
3.
BérardA, SheehyO. The Quebec Pregnancy Cohort–prevalence of medication use during gestation and pregnancy outcomes. PLoS One, 2014; 9(4):e93870; doi: 10.1371/journal.pone.0093870
4.
MitchellAA, GilboaSM, WerlerMM, et al.Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. American Journal of Obstetrics and Gynecology, 2011; 205(1):51.e1-51–e8; doi: 10.1016/j.ajog.2011.02.029
5.
BowieAC, WerlerMM, VelezMP, et al.Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: A population-based cohort study. Cmaj, 2022; 194(5):E152–e162; doi: 10.1503/cmaj.211215
6.
YazdyMM, DesaiRJ, BroglySB. Prenatal exposures and short and long term developmental outcomes: Prescription opioids in pregnancy and birth outcomes: A review of the literature. Journal of Pediatric Genetics, 2015; 4(2):56; doi: 10.1055/s-0035-1556740
7.
HeyranaK, ByersHM, StrattonP. Increasing the participation of pregnant women in clinical trials. Jama, 2018; 320(20):2077–2078; doi: 10.1001/jama.2018.17716
8.
AndradeSE, GurwitzJH, DavisRL, et al.Prescription drug use in pregnancy. American Journal of Obstetrics and Gynecology, 2004; 191(2):398–407; doi: 10.1016/j.ajog.2004.04.025
9.
OulmanE, KimTHM, YunisK, et al.Prevalence and predictors of unintended pregnancy among women: An analysis of the Canadian Maternity Experiences Survey. BMC Pregnancy and Childbirth, 2015; 15(1):260; doi: 10.1186/s12884-015-0663-4
10.
YoungFB, DuralO, CookJ, et al.Trends and predictors of unintended pregnancy in Canada: Results from a national survey. Journal of Obstetrics and Gynaecology Canada, 2020; 42(5):695–695; doi: 10.1016/j.jogc.2020.02.119
11.
MatsuiD. Adherence with drug therapy in pregnancy. Obstetrics and Gynecology International, 2012:796590; doi: 10.1155/2012/796590
12.
LunskyY, KhuuW, TadrousM, et al.Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities. The Canadian Journal of Psychiatry, 2018; 63(6):361–369; doi: 10.1177/0706743717727240
13.
EricksonSR, KamdarN, WuC-H. Adverse medication events related to hospitalization in the United States: A comparison between adults with intellectual and developmental disabilities and those without. American Journal on Intellectual and Developmental Disabilities, 2020; 125(1):37–48; doi: 10.1352/1944-7558-125.1.37
14.
TarasoffLA, LunskyY, ChenS, et al.Preconception health characteristics of women with disabilities in Ontario: A population-based, cross-sectional study. Journal of Women’s Health, 2020; 29(12):1564–1575; doi: 10.1089/jwh.2019.8273
15.
BrownHK, ChenS, GuttmannA, et al.Rates of recognized pregnancy in women with disabilities in Ontario, Canada. Am J Obstet Gynecol, 2020; 222(2):189–192; doi: 10.1016/j.ajog.2019.10.096
16.
SubramanianA, Azcoaga-LorenzoA, AnandA, et al.Polypharmacy during pregnancy and associated risk factors: A retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000–2019. BMC Med, 2023; 21(1):21; doi: 10.1186/s12916-022-02722-5
17.
RichardCL, LoveBL, BoghossianN, et al.Are pregnant women with disability prescribed opioids more and at higher dosages than those without disability?: A retrospective cohort study of South Carolina Medicaid beneficiaries. Disability and Health Journal, 2022; 15(2):101288; doi: 10.1016/j.dhjo.2022.101288
18.
BoothEJ, KitsantasP, MinH, et al.Disability and opioids among pregnant women. Women’s Reproductive Health, 2022; 11(1):1–16; doi: 10.1080/23293691.2022.2150105
19.
GarcíaMH, PetersenJM, ParkerSE, et al.Medication use during pregnancy among women with congenital physical disabilities. Birth Defects Research, 2022; 114(14):785–796; doi: 10.1002/bdr2.2048
20.
VigodSN, GomesT, WiltonAS, et al.Antipsychotic drug use in pregnancy: High Dimensional, Propensity Matched, Population Based Cohort Study. bmj, 2015; 350:h2298; doi: 10.1136/bmj.h2298
21.
VigodS, KurdyakP, DennisC, et al.Maternal and newborn outcomes among women with schizophrenia: A retrospective population‐based cohort study. BJOG: An International Journal of Obstetrics & Gynaecology, 2014; 121(5):566–574; doi: 10.1111/1471-0528.12567
22.
MartinsD, SinghS, KhuuW, et al.Linking the Narcotics Monitoring System Database to Quantify the Contribution of Prescribed and Non-Prescribed Opioids to Opioid Overdoses in Ontario, Canada. IJPDS, 2018; 3(4); doi: 10.23889/ijpds.v3i4.644
23.
ChiuM, LebenbaumM, LamK, et al.Describing the linkages of the immigration, refugees and citizenship Canada permanent resident data and vital statistics death registry to Ontario’s administrative health database. BMC Medical Informatics and Decision Making, 2016; 16(1):135; doi: 10.1186/s12911-016-0375-3
24.
VarnerCE, ParkAL, LittleD, et al.Emergency department use by pregnant women in Ontario: A retrospective population-based cohort study. Canadian Medical Association Open Access Journal, 2020; 8(2):E304–E312; doi: 10.9778/cmajo.20190154
25.
Von ElmE, AltmanDG, EggerM, et al.The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. International Journal of Surgery, 2014; 12(12):1495–1499; doi: 10.1016/j.jclinepi.2007.11.008
26.
BenchimolEI, SmeethL, GuttmannA, et al.The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med, 2015; 12(10):e1001885; doi: 10.1371/journal.pmed.1001885
27.
AkerAM, StephensonAL, WiltonAS, et al.Asthma Severity and Control and Their Association With Perinatal Mental Illness. The Canadian Journal of Psychiatry, 2022; 67(2):156–159; doi: 10.1177/07067437211039790
28.
DarneyBG, BielFM, QuigleyBP, et al.Primary cesarean delivery patterns among women with physical, sensory, or intellectual disabilities. Women’s Health Issues, 2017; 27(3):336–344; doi: 10.1016/j.whi.2016.12.007
29.
LinE, BaloghR, CobigoV, et al.Using administrative health data to identify individuals with intellectual and developmental disabilities: A comparison of algorithms. Journal of Intellectual Disability Research, 2013; 57(5):462–477; doi: 10.1111/jir.12002
30.
SarayaniA, AlbogamiY, ThaiTN, et al.Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. Am J Obstet Gynecol, 2022; 227(2):263.e1-263–e38; doi: 10.1016/j.ajog.2022.01.004
31.
MasnoonN, ShakibS, Kalisch-EllettL, et al.What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 2017; 17:1–10; doi: 10.1186/s12877-017-0621-2
32.
MathesonFI, DunnJR, SmithKL, et al.Development of the Canadian Marginalization Index: A new tool for the study of inequality. Can J Public Health, 2012; 103(8 Suppl 2):S12–6; doi: 10.1007/bf03403823
33.
RichardL, HwangSW, ForchukC, et al.Validation study of health administrative data algorithms to identify individuals experiencing homelessness and estimate population prevalence of homelessness in Ontario, Canada. BMJ Open, 2019; 9(10):e030221; doi: 10.1136/bmjopen-2019-030221
34.
CamdenA, RayJG, ToT, et al.Identification of Prenatal Opioid Exposure Within Health Administrative Databases. Pediatrics, 2021; 147(1); doi: 10.1542/peds.2020-018507
35.
Johns Hopkins School of Public Health. The Johns Hopkins CGH system: technical reference guide version 10.0. Johns Hopkins School of Public Health; 2013.
36.
DesaiRJ, HuybrechtsKF, Hernandez-DiazS, et al.Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: Population based cohort study. bmj, 2015; 350:h2102; doi: 10.1136/bmj.h2102
37.
PatrickSW, DudleyJ, MartinPR, et al.Prescription opioid epidemic and infant outcomes. Pediatrics May 2015; 135(5):842–850; doi: 10.1542/peds.2014-3299
38.
Team MR. Mental Health and Addictions System Performance in Ontario: 2021 Scorecard. ON: ICES; 2021.
39.
SaundersNR, GuanJ, FuL, et al.Periodic health visits by primary care practice model, a population-based study using health administrative data. BMC Family Practice. 2019/03/05, 2019; 20(1):42; doi: 10.1186/s12875-019-0927-6
40.
AustinPC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics-Simulation and Computation, 2009; 38(6):1228–1234; doi: 10.1080/03610910902859574
41.
ZouG. A modified poisson regression approach to prospective studies with binary data. American Journal of Epidemiology, 2004; 159(7):702–706; doi: 10.1093/aje/kwh090
42.
MitraM, ClementsKM, ZhangJ, et al.Maternal Characteristics, Pregnancy Complications, and Adverse Birth Outcomes Among Women With Disabilities. Med Care, 2015; 53(12):1027–1032; doi: 10.1097/mlr.0000000000000427
43.
Huezo GarcíaM, ParkerSE, PetersenJM, et al.Birth outcomes among women with congenital neuromuscular disabilities. Disabil Health J, 2022; 15(2):101259; doi: 10.1016/j.dhjo.2021.101259
44.
SignoreC, DavisM, TingenCM, et al.The Intersection of Disability and Pregnancy: Risks for Maternal Morbidity and Mortality. J Womens Health (Larchmt) Feb 2021; 30(2):147–153; doi: 10.1089/jwh.2020.8864
45.
TsiourisJA. Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: Treatment or mistreatment? J Intellect Disabil Res, 2010; 54(1):1–16; doi: 10.1111/j.1365-2788.2009.01232.x
46.
ShroffS, McNeilM, BorreroS. An Innovative Framework to Improve Teratogenic Medication Risk Counseling. J Midwifery Womens Health May 2017; 62(3):353–357; doi: 10.1111/jmwh.12604
47.
Halli-TierneyAD, ScarbroughC, CarrollD. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician, 2019; 100(1):32–38.
48.
SaeedG, BrownHK, LunskyY, et al.Barriers to and facilitators of effective communication in perinatal care: A qualitative study of the experiences of birthing people with sensory, intellectual, and/or developmental disabilities. BMC Pregnancy and Childbirth. 2022/04/26, 2022; 22(1):364; doi: 10.1186/s12884-022-04691-2
49.
SmithMVA, AdamsD, CarrC, et al.Do people with intellectual disabilities understand their prescription medication? A scoping review. J Appl Res Intellect Disabil, 2019; 32(6):1375–1388; doi: 10.1111/jar.12643
50.
ThompsonD, ThomasH, SolomonJ, et al.Chronic illness, reproductive health and moral work: Women’s experiences of epilepsy. Chronic Illn, 2008; 4(1):54–64; doi: 10.1177/1742395307086696
51.
World Health Organization. Medication safety in polypharmacy: technical report. 2019.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
